The most common local adverse events associated
with ICS therapy are oropharyngeal candidiasis (also
known as oral thrush) and dysphonia (hoarseness, difficulty
speaking). Rinsing and expectorating (spitting)
after each inhalation and/or the use of a spacer device
can help reduce the risk of these side effects. Systemic
adverse effects with ICS therapy are rare, but may
include adrenal suppression, changes in bone density,
cataracts, glaucoma and growth retardation [4].